Pharmacogenomics in routine medical care;Pharmakogenomik in der Praxis

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 4, 2010, Pages 133-144

  Rosskopf, D ^a   Meyer Zu Schwabedissen, H E ^a   Kroemer, H K ^a   Siegmund, W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cytochrome P450 2D6; Drug Transport; Pharmacogenetics; Pharmacogenomics; Rhabdomyolysis, statin induced; SLCO1B1; Thiopurine Methyltransferase (TPMT)

Indexed keywords

ACENOCOUMAROL; AZATHIOPRINE; BOSENTAN; CANDESARTAN; CEFTRIAXONE; CELECOXIB; CLARITHROMYCIN; CODEINE; CYTOCHROME P450 2D6; FLUINDOSTATIN; FLUOXETINE; FLURBIPROFEN; GLIMEPIRIDE; GLIPIZIDE; IBUPROFEN; IRBESARTAN; ISONIAZID; MACROLIDE; MERCAPTOPURINE; MORPHINE; NALOXONE; PAROXETINE; PROCAINAMIDE; SALAZOSULFAPYRIDINE; SULFAMETHOXAZOLE; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNINDEXED DRUG; VORICONAZOLE; ANTICOAGULANT AGENT; ANTITUSSIVE AGENT; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; HYPOCHOLESTEROLEMIC AGENT; METHYLTRANSFERASE; NARCOTIC AGENT; ORGANIC ANION TRANSPORTER; PHENPROCOUMON; SIMVASTATIN; SLCO1B1 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE; WARFARIN;

DRUG ANTAGONISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSPORT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MEDICAL CARE; PHARMACOGENOMICS; PHENOTYPE; REVIEW; ADOLESCENT; ADULT; ALLELE; BIOAVAILABILITY; BIOTRANSFORMATION; CASE REPORT; DRUG COMBINATION; DRUG DETOXIFICATION; FEMALE; GENETICS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PERSONALIZED MEDICINE; PHARMACOGENETICS; POINT MUTATION;

ADOLESCENT; ADULT; ALLELES; ANTICHOLESTEREMIC AGENTS; ANTICOAGULANTS; ANTITUSSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CODEINE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; METABOLIC CLEARANCE RATE; METABOLIC DETOXICATION, DRUG; METHYLTRANSFERASES; MIDDLE AGED; NARCOTICS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; PHENOTYPE; PHENPROCOUMON; POINT MUTATION; POLYMORPHISM, GENETIC; SIMVASTATIN; WARFARIN;

EID: 75649123474     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0029-1244830     Document Type: Review

References (40)

1. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood 2008 111 16-24
2. Chung W H., Hung S I., Hong H S., et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004 428 486
3. Collet J P., Hulot J S., Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009 373 309-317
4. Eichelbaum M, Ingelman-Sundberg M, Evans W E. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006 57 119-137
5. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979 16 183-187
6. Evans D A. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci 1968 151 723-733
7. Fujita K, Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab 2007 8 554-562
8. Gage B F. Pharmacogenetics-based coumarin therapy. Hematology Am Soc Hematol Educ Program 2006 467-473
9. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004 351 2827-2831
10. Giacomini K M., Brett C M., Altman R B., et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007 81 328-345
11. Giacomini K M., Krauss R M., Roden D M., et al. When good drugs go bad. Nature 2007 446 975-977
12. Goetz M P., Loprinzi C L. A hot flash on tamoxifen metabolism. J Natl Cancer Inst 2003 95 1734-1735
13. Goetz M P., Rae J M., Suman V J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005 23 9312-9318
14. Goldstein D B., Tate S K., Sisodiya S M. Pharmacogenetics goes genomic. Nat Rev Genet 2003 4 937-947
15. Gonzalez F J., Skoda R C., Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988 331 442-446
16. Ho P M., Maddox T M., Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 301 937-944
17. Juurlink D N., Gomes T, Ko D T., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180 713-718
18. Kalow W, Staron N. On distribution and inheritance of atypical forms of human serum cholinesterase, as indicated by dibucaine numbers. Can J Biochem Physiol 1957 35 1305-1320
19. Karapetis C S., Khambata-Ford S, Jonker D J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008 359 1757-1765
20. Kawanishi C, Lundgren S, Agren H, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004 59 803-807
21. Kuijer P M., Hutten B A., Prins M H., et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999 159 457-460
22. Leipold G, Schutz E, Haas J P., et al. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997 40 1896-1898
23. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy a genomewide study. N Engl J Med 2008 359 789-799
24. Mahgoub A, Idle J R., Dring L G., et al. Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977 2 584-586
25. Maitland M L., Vasisht K, Ratain M J. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci 2006 27 432-437
26. Mallal S, Phillips E, Carosi G, et al. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med 2008 358 568-579
27. Mardis E R. The impact of next-generation sequencing technology on genetics. Trends Genet 2008 24 133-141
28. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008 26 1789-1796
29. Oldenburg J, Bevans C G., Fregin A, et al. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007 98 570-578
30. Qazim B, Stollberger C, Krugluger W, et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Thrombolysis 2009 28 211-214
31. Rieder M J., Reiner A P., Gage B F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005 352 2285-2293
32. Rosskopf D, Kroemer H K., Siegmund W. [Pharmacokinetic problems in clinical practice: role of drug transporters]. Dtsch Med Wochenschr 2009 134 345-356
33. Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008 64 753-767
34. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007 25 5187-5193
35. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 360 363-375
36. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005 293 1485-1489
37. Thompson P D., Clarkson P, Karas R H. Statin-associated myopathy. JAMA 2003 289 1681-1690
38. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005 44 1227-1246
39. Urso M L., Clarkson P M., Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 2005 25 2560-2566
40. Zanger U M., Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 369 23-37